09 Nov2013
CCM Duopharma, Korea’s PanGen to test kidney drug, potential RM50mil rights
Published: Friday November 1, 2013 MYT 4:20:00 PM
Updated: Friday November 1, 2013 MYT 4:40:04 PM
A technician at work at CCM Duopharma Biotech Bhd’s plant. CCMD will have commercialisation rights for the marketing and distribution in Malaysia, Singapore and Brunei, worth more than RM50mil annually if clinical trials of the PDA10 prove successful.
KUALA LUMPUR: CCM Duopharma Biotech Bhd (CCMD) and South Korea’s PanGen Biotech will conduct phase three clinical trials of the latter’s PDA10 drug to treat patients with anemia due to chronic kidney failure.
KUALA LUMPUR, 24 Sept 2013 – Can patients with heart problems or people suffering the agonising pain of osteoarthritis be cured without medication or major surgery?